Market Overview

UPDATE: Piper Jaffray Raises PT to $32 on AmSurg; Long-Term Outlook Positive

Related AMSG
Updated Research Report on AmSurg - Analyst Blog
10 Healthcare Stocks With Strong Growth For 2014: Investment Idea Of The Day

Piper Jaffray maintained AmSurg (NASDAQ: AMSG) with a Neutral rating and raised the price target from $30.00 to $32.00.

Piper Jaffray commented, "We expect AMSG to trade down on mixed Q4 results and FY13 EPS guidance that was lower than Street estimates. Q4 revenues beat, while EPS missed Street expectations due to higher than expected interest expense relative to our model. While FY13 revenue guidance was fine, EPS was lower than expected. AMSG did see a slight uptick in GI procedures due to colon cancer screening and same-center growth of 3% was better than anticipated. We believe the overall environment remains stable and management noted hospitals are proactively reaching out to the company regarding partnership opportunities, which is a long-term positive."

AmSurg closed at $31.26 on Monday.

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (AMSG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free